A Registry to Form a Long-Term Therapeutic and Research Network for Hepatitis C

Overview

About this study

The primary purpose of the study is to establish a long-term nationwide registry of patients undergoing treatment with antiviral therapies for chronic hepatitis C at academic and community practices.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

Adult age 18 or older
Being treated with antiviral HCV treatment regimens that contain telaprevir or boceprevir

Exclusion Criteria

Inability to provide written informed consent
Currently participating in another clinical trial of hepatitis C therapeutics
- Studies comparing HCV RNA assays are not considered exclusionary

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Jacksonville, Fla. Mayo Clinic principal investigator Surakit Pungpapong, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Jacksonville, Fla.

Mayo Clinic principal investigator

Surakit Pungpapong, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials